MedTrace Logo

Escitalopram and the Risk of Serious Adverse Events

NCT07274241 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12145

Last updated 2026-01-30

No results posted yet for this study

Summary

The goal of this population-based cohort study is to assess the safety of initiating a new outpatient prescription of 10mg/day of Escitalopram (higher dose) compared to 5 mg/day (lower dose) in adults over the age of 65 with low kidney function.

Primary question

Whether initiating a new outpatient prescription of a higher dose of Escitalopram (10mg/day) compared to a lower dose (5 mg/day) in older adults with low kidney function (an eGFR \<45 mL/min per 1.73 m2 but not receiving dialysis or having a history of kidney transplantation) is associated with a higher 30-day risk of a composite outcome of all-cause hospitalization, all-cause emergency department visit, or all-cause mortality?

Conditions

  • Chronic Kidney Disease (CKD)
  • Elderly
  • Outpatient

Interventions

DRUG

Escitalopram

The primary exposure of interest will be oral Escitalopram at a dose of 5 or 10 mg/day.

Sponsors & Collaborators

  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

    lead OTHER

Principal Investigators

  • Amit Garg, MD, PhD · London Health Sciences Centre Research Institute

Eligibility

Min Age
66 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-01
Primary Completion
2025-01-01
Completion
2025-11-15

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07274241 on ClinicalTrials.gov